The NHL Players’ Association has approved a drug that can be administered to players with severe chronic bronchitis to help them get the medication that they need to stay in the game.
The NHLPA approved the medication, Cephrix, as part of its health plan that has been in place since the start of the season.
It is a cortisolone.
Cephrix was approved by the US Food and Drug Administration in June and has been on the market since September.
Players who have had severe cases of chronic bronchiectasis, which is a type of chronic lung disease, can be treated with Cephix.
The medication is used to treat chronic coughs and wheezing.
The medication has not been approved by doctors in the United States for use in players with a diagnosis of chronic or severe bronchial asthma.
The NHLPA’s health plan is designed to help players manage their symptoms and keep them from returning to the ice.
The plan also includes supplemental therapy for the management of acute respiratory infections.
Players will also be allowed to use the medication once every two weeks during the season, the union said.
Players who are on the health plan and are experiencing severe bronchiectionasis will be required to use Cephaxone to take the medication.
It costs about $40 a dose.
The union has not specified how much the medication will cost.
The union said that it does not want to make it easier for players to take Cephxone if it is not approved for use by doctors.
Cephlex is not currently approved for the treatment of chronic respiratory diseases.
Players have been asked to be on the NHL’s health care plan for six months.
The health plan allows players to keep their team and their insurance if they are on it.
The Cephxi drug was approved in June by the U.S. Food and Tobacco Administration, which also approved a new treatment for patients with COPD, or chronic obstructive pulmonary disease, and the use of a different drug, Prozac, to treat patients with other respiratory diseases such as asthma and COPD.